Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8026281 | LUPIN | Treating metabolic syndrome with fenofibrate |
Apr, 2025
(2 years from now) | |
US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(10 years from now) |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia
Dosage: CAPSULE;ORAL
3
United States
1
IB
1
Switzerland
1
India
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9750822 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US7635773 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US8410077 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US9200088 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US9493582 | LUPIN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) |
Drugs and Companies using FOSPHENYTOIN SODIUM ingredient
Market Authorisation Date: 05 November, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
14
United States
8
Japan
5
China
4
Korea, Republic of
3
Australia
3
Canada
3
Mexico
3
European Union
2
Hong Kong
2
Israel
2
Russia
1
New Zealand
1
EA
1
Brazil
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10857133 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11324721 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
US10335390 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11000507 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11020377 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11000508 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
US10682338 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US10849884 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 15, 2022 |
New Indication (I) | Jun 30, 2024 |
New Patient Population (NPP) | Jan 26, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: 2026-09-15
Market Authorisation Date: 15 September, 2017
Treatment: Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in adults; Treatment of trichomoniasis in patients 12 years of age and older
Dosage: GRANULE;ORAL
13
United States
4
Korea, Republic of
4
Japan
3
Australia
2
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic